Oncology and Carcinogenesis articles for France

Time frame: 1 May 2025 - 30 April 2026

View topic

Count: 352

Article ‘Count’ for Oncology and Carcinogenesis.

Journal Count Share
5 3.56
A Modular Supramolecular Peptide Platform Reveals Atomic-Number-Dependent Mechanisms Driving Radioenhancement 1.00
Efficiently Reversing Immunotherapy Resistance in Lung Cancer by an Inhalable 2D Molybdenum Disulfide T Cell Hyperactivation Platform 0.13
The Uptake of Metallic Nanoparticles in Breast Cancer Cell Lines is Modulated by the Hyaluronan-CD44 Axis 1.00
Monitoring Whole-Body Inflammation with Gallium-68-Labeled Polydopamine Iron Oxide Particles via Hybrid Immuno-PET-MRI 0.75
Scavenging Reactive Oxygen Species by Cerium Oxide Nanoparticles Prevents Death in a Peripheral T Cell Lymphoma Preclinical Mouse Model 0.69
3 1.19
Non-destructive assessment of multi-material micro-tissue mechanics reveals the critical role of rigidity gradients in tumour growth and pressure 1.00
Inter-Spheroid Proximity and Matrix Remodeling Determine Cancer Associated Fibroblast Mediated Cancer Cell Invasion 0.06
Insights into the osteosarcoma microenvironment: Multiscale analysis of structural and mineral heterogeneity 0.13
3 0.55
Shaping Ti3C2 MXene Nanospheres for Precision Near-Infrared Photothermal Therapy 0.05
Laser Engineering of HfN-Based Nanoparticles for Safe NIR-I Photothermal and X-ray Enhancing Cancer Therapies 0.13
MPI‐Guided Photothermal Therapy of Prostate Cancer Using Stem Cell Delivery of Magnetotheranostic Nanoflowers 0.38
2 2.00
Unraveling the impact of VHL exon 2 mutations in erythrocytosis or von Hippel-Lindau disease identified RNA-binding proteins involved in VHL splicing 1.00
Allele-specific RNAi therapy corrects an extracellular matrix defect in Schuurs-Hoeijmakers syndrome 1.00
1 0.33
Application of a Multiomics Imaging Workflow to Explore Asparlas Treatment in Solid Tumors 0.33
2 0.19
Organoplatinum(II) J‐Aggregates with Prolonged Triplet Lifetimes for Enhanced Photodynamic and Photocatalytic Therapy 0.06
Boosting Cancer Chemoimmunotherapy with Mitochondria-Targeting Iridium(III)-Based Immunogenic Oncosis Inducers 0.13
1 0.05
Antithrombotic Therapy Discontinuation, Bleeding, and Thromboembolic Events in Patients With Cancer During the Last Phase of Life: Insights From Primary Care Records 0.05
6 1.52
The International Study Group for Pancreatic Surgery (ISGPS) Definition and Classification of Postpancreatectomy Mortality. 0.05
Setting the Standard in Robotic Whipple Surgery: International Multicenter Benchmark Analysis. 0.15
Accuracy of Histology and Malignancy Grade between Preoperative Biopsy and Surgical Specimens in Primary Retroperitoneal Sarcoma. A Study from the Prospective Retroperitoneal Sarcoma Registry (Resar). 0.06
Recurrence-free Survival as a Surrogate Endpoint for Overall Survival in Resectable Esophageal Cancer: Integrated Analysis of Individual Patient Data From Phase III Trials. 0.10
Prognostic Impact of type of Arterial Resection on Outcomes of Pancreatectomy with Arterial Resection for Pancreatic Adenocarcinoma. 1.00
Recommendations on Perihilar Cholangiocarcinoma. The Milan Jury-Based Consensus. 0.15
1 1.00
Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series 1.00
14 4.27
Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia 0.06
Menin inhibition with revumenib for iNPM1/i-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study 0.11
A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma 0.13
Type 2 calreticulin mutations activate ATF6 to promote BCL-xL–mediated survival in myeloproliferative neoplasms 0.08
Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results 0.55
Magrolimab plus azacitidine vs physician’s choice for untreated iTP53/i-mutated acute myeloid leukemia: the ENHANCE-2 study 0.05
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy 0.09
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia 0.10
Large-scale dependency and drug screens to characterize the therapeutic vulnerabilities of multiple myeloma with 1q+ 0.04
Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial 0.94
Surface pTα expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL 1.00
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma. 0.07
Phase 1/2 Trial of Anti-CD7 Allogeneic WU-CART-007 in patients with Relapsed/Refractory T-cell Malignancies 0.06
Efficacy and safety of azacitidine in VEXAS syndrome: a large-scale retrospective study from the FRENVEX 1.00
3 0.22
Management of gastric cancer peritoneal metastasis: International Gastric Cancer Association GCPM Working Group consensus statements 0.02
Survival After Pathological Complete Response Following Neoadjuvant Chemotherapy vs Chemoradiotherapy in Esophageal Squamous Cell Carcinoma 0.10
Evaluation of pathological complete response as a surrogate endpoint for overall survival in resectable oesophageal cancer: integrated analysis of individual patient data from phase III trials 0.10
1 0.13
RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition 0.13
11 5.71
An Extracellular Matrix-Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation. 0.87
ESR1 Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer. 0.14
Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients. 0.93
Tumor-Associated Macrophages Produce PGE2 to Promote CD8+ T Cell Exhaustion and Drive Resistance to PD-L1 Blockade in Microsatellite Stable Colorectal Cancer. 1.00
In Silico Digital Twins of Bone Metastasis Enable Investigation of Tumor Progression and Therapy Response 0.07
Mutant and Wild-type RAS Crosstalk and Stoichiometric Deficiencies are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma. 0.04
Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma. 0.89
PRT3789 is a First-in-Human SMARCA2-Selective Degrader that Induces Synthetic Lethality in SMARCA4-Mutated Cancers. 0.10
Modeling the PAX5P80R Mutation Reveals HIF2α Activation as a Common Feature and Therapeutic Target in B-cell Acute Lymphoblastic Leukemia 1.00
Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy 0.14
De Novo Serine Synthesis Is a Metabolic Vulnerability That Can Be Exploited to Overcome Sunitinib Resistance in Advanced Renal Cell Carcinoma 0.54
1 0.11
Extracellular GPX4 impairs antitumor immunity via dendritic ZP3 receptors 0.11
1 1.00
Bambusuril as an effective astatide sequestrating agent by hydrogen bonding 1.00
1 1.00
The impact of dual cannabis and tobacco smoking in young patients with lung cancer: results from the prospective “Environment and Lung Cancer” study 1.00
3 1.11
Novel Plasma Proteomic Markers and Risk of Venous Thromboembolism. 0.04
Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design. 0.78
Breast Cancer Reveals Latent BMPR2-Related Susceptibility to Pulmonary Hypertension 0.30
1 0.36
Cohesin and its regulation promote monopolar kinetochore orientation at meiosis I in Arabidopsis 0.36
2 0.13
CircRNA-encoded RIPK1-98 protein drives lung adenocarcinoma progression 0.07
Multiscale mechanisms driving tissue rupture by invading cells 0.06
1 0.33
Trifloxystrobin induces oxidative stress-dependent activation of the OMA1-DELE1-HRI integrated stress response leading to apoptosis in human neuroblastoma cells 0.33
7 2.21
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends 0.50
Erdafitinib in Patients with High- and Intermediate-risk Non–muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study 0.05
Stereotactic Intensity-modulated Radiotherapy After Radical Prostatectomy (SCIMITAR): 4-Year Outcomes of a Phase 2 Clinical Trial 0.15
CaboPoint: A Phase 2 Study of Second-line Cabozantinib After Checkpoint Inhibitor–based Combination Therapy in Patients with Metastatic Renal Cell Carcinoma 0.31
Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial 1.00
First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial 0.10
Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial 0.10
2 1.15
Does a long time to colonoscopy after a positive faecal immunochemical test result have a deleterious impact on colorectal cancer outcomes? A nationwide cohort study 1.00
Hereditary diffuse gastric cancer spectrum associated with germline iCTNNA1/i loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls 0.15
5 1.26
NEDD8-specific protease 1 deficiency as a novel driver of hepatoblastoma development through dysregulation of the CAND1-NEDD8 pathway. 0.03
Satellite lesions versus intrahepatic metastasis in multifocal intrahepatic cholangiocarcinoma: Prognostic impact and genomic profiling. 0.05
Laser-activated nanoparticles rewire tumor microenvironment enhancing PD-1 blockade and T cell response in cholangiocarcinoma. 1.00
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries' framework for digital twin advancement. 0.08
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial. 0.10
1 1.00
Detection of minimal residual disease in cryopreserved testicular tissue from (pre)pubertal boys with acute leukemia following first-line therapy 1.00
1 1.00
Active Prostate Phantom with Multiple Chambers 1.00
3 1.88
Synthesis, Characterization, and Evaluation of Chelators for Radium-223 0.33
Advanced 64Cu/67Cu-Based Theranostics: Application of the Copper Chelator TE1PA to a Murine Model of HER2-Positive Gastric Cancer 1.00
Protoporphyrin IX-Derived Ruthenium(II) Complexes for Photodynamic Therapy in Gastric Cancer Cells 0.55
7 2.56
Development and validation of an epidemiological risk score for early detection of pancreatic cancer in high-risk individuals within the IMAGene project 0.11
The impact of an organized screening program on gastric cancer incidence: a quasi-experimental study 0.07
Kidney cancer and occupational agricultural exposures in the AGRIculture and CANcer cohort 1.00
Using Mendelian randomization to investigate etiologic heterogeneity across renal cell carcinoma subtypes 0.25
Investigating the association between anthropometry and colorectal cancer survival: a two-sample Mendelian randomization analysis 0.03
Lifetime occupational and para-occupational exposure to organic solvents and testicular germ cell tumor risk: a French case–control study—TESTIS 1.00
Maternal prenatal infection and childhood leukaemia: a Childhood Cancer and Leukemia International Consortium (CLIC) meta-analysis 0.10
2 0.08
International Reference Values for Surgical Outcomes of Total Pancreatectomy 0.04
Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer 0.04
1 0.02
Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis 0.02
1 0.03
Integrated analysis of the adipocyte plasma membrane proteome reveals KCC1 and PIT2 as novel insulin-responsive transporters 0.03
3 2.25
Mechanical coordination between anaphase A and B drives asymmetric chromosome segregation 0.71
Roles of Srs2/PARI-family DNA helicases in NoCut checkpoint signaling and abscission regulation 0.83
Moesin controls cell–cell fusion and osteoclast function 0.70
5 2.11
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma 0.04
PTBP1 variants displaying altered nucleocytoplasmic distribution are responsible for a neurodevelopmental disorder with skeletal dysplasia 0.32
Targeting peroxiredoxin 2 prevents hepatocarcinogenesis in metabolic liver disease models 0.71
Mutations in spliceosomal gene SNW1 cause neurodevelopment disorders with microcephaly 0.04
Co-targeting TGF-β and PD-L1 sensitizes triple-negative breast cancer to experimental immunogenic cisplatin-eribulin chemotherapy doublet 1.00
38 8.31
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer. 0.05
Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP. 1.00
Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide. 0.09
Residual Absolute Volume of Blastema as a Predictor of Clinical Outcomes in Patients With Wilms Tumor: A Report From the SIOP WT 2001 Study. 0.14
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study. 0.01
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer. 0.12
Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm. 0.17
Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial. 1.00
Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and FGFR Alterations: Final Results From the Phase II NORSE Study. 0.08
Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer. 0.21
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial. 0.17
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. 0.04
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer. 0.14
Gemcitabine intravesical system plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with MIBC: primary analysis and biomarker results of SunRISe-4. 0.14
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial. 0.23
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2 0.06
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation. 0.23
TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma. 0.36
Ifinatamab Deruxtecan in Patients With Extensive-Stage Small-Cell Lung Cancer: Primary Analysis of the Phase 2 IDeate-Lung01 Trial. 0.13
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis. 0.11
Ziftomenib in Relapsed or Refractory NPM1-Mutated AML. 0.13
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B). 0.13
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study. 0.10
Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay. 0.92
Deep Learning Model for Breast Shear Wave Elastography to Improve Breast Cancer Diagnosis (INSPiRED 006): An International, Multicenter Analysis. 0.04
Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial. 0.22
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study. 0.04
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas 0.07
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation. 0.06
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. 0.08
RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE). 0.14
BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203. 0.28
Isatuximab Subcutaneous by On-Body Delivery System vs Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 3 IRAKLIA Study. 0.13
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. 0.17
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study. 0.05
PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma. 1.00
Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database. 0.29
Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes. 0.04
3 0.29
Defects in intron recycling suppress the antiviral response via a mechanism of intronic endogenous dsRNA 0.07
The assembly of cancer-specific ribosomes by the lncRNA LISRR suppresses melanoma anti-tumor immunity 0.06
Tumor-instructed glutamine synthesis in cancer-associated fibroblasts promotes pro-tumor macrophages 0.15
3 1.16
Targeting ATR to overcome cisplatin resistance in hepatoblastoma 0.99
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma 0.12
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study 0.05
2 0.49
Profiling Human Papillomavirus Lineage-Specific Capsid Antigenicity With Geographically Diverse Natural Infection Antibodies 0.18
The Diagnostic Value of Soluble Epstein-Barr Virus BZLF1 Protein in Posttransplant Lymphoproliferative Disease Among Solid Organ and Hematopoietic Cell Transplant Recipients 0.31
1 1.00
Surgery for Thymic Malignancy and Non-Thymic Malignancy Incidence: A national longitudinal study. 1.00
3 0.71
Potent Biological Activity by a Synthetic Cu(I) Cationophore Redistributing Intracellular Copper Pools 0.45
π-Extended Ru–COUBPY Photosensitizers for In Vivo Anticancer Phototherapy Using One-Photon 780 nm Near-Infrared Light 0.19
Structure over States: Planarity, Not Energy, Dictates Photoactivation in Ru(II) PACT Agents 0.07
11 2.84
Conditional recurrence-free survival after curative esophagectomy: individual patient data analysis of 11 trials 0.10
A smoking-related plasma protein score and smoking-related cancer risk and mortality in ARIC 0.15
Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis 0.04
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers 0.02
Assessing the oncologic risk when systematic and multiparametric magnetic resonance imaging-targeted prostate biopsy grade groups are discordant 0.13
Increase of early-onset colorectal cancer: a cohort effect 1.00
Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: the RASINTRO prospective multicenter study 0.98
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer 0.07
Survival deficits in young women with breast cancer in sub-Saharan Africa: the African Breast Cancer–Disparities in Outcomes cohort 0.17
Discovering plasma proteins associated with breast cancer incidence in post-menopausal women in ARIC 0.08
Breastfeeding after breast cancer in young iBRCA/i carriers 0.12
2 0.52
MRE11 proximal polyadenylation site-mediated looping impacts transcription and genomic stability 0.18
PARP1 auto-modification promotes faithful Okazaki fragment processing and limits replication fork speed 0.33
1 1.00
Photodynamic Therapy Using Pulsed-Laser Irradiation of Gold Nanoparticles for the Treatment of Cancers with High Basal Oxidative Stress 1.00
12 4.22
Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1 1.00
Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer 1.00
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer 0.07
The integrated stress response promotes immune evasion through lipocalin 2 0.03
Cross-regulation of [2Fe–2S] cluster synthesis by ferredoxin-2 and frataxin 1.00
Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma 0.04
Lymph node environment drives FSP1 targetability in metastasizing melanoma 0.13
SPP1 is required for maintaining mesenchymal cell fate in pancreatic cancer 0.03
Molecular subtypes of human skeletal muscle in cancer cachexia 0.14
A missing enzyme-rescue metabolite as cause of a rare skeletal dysplasia 0.04
The mutagenic forces shaping the genomes of lung cancer in never smokers 0.04
Activation of lysosomal iron triggers ferroptosis in cancer 0.70
53 17.60
2′--methylation-dependent installation of -methylguanosine in the U6 internal stem loop facilitates efficient spliceosome assembly 0.19
Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients 0.03
Nonsense-mediated mRNA decay factors target short poly(A)-tailed mRNAs lacking a premature termination codon 1.00
Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study 0.02
Clinicopathologic and molecular predictors of survival in -deficient tubo-ovarian high-grade serous carcinoma 0.01
Bleb-based extravasation uses conserved morphodynamics but divergent calcium control 0.13
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study 0.06
Both genome instability and replicative senescence stem from the shortest telomere in telomerase-negative cells 0.81
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in G12C-mutant advanced solid tumors: a first-in-human study 0.15
Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy 0.01
USP7 deubiquitinase stabilizes FAN1 to support DNA crosslink repair and suppress CAG repeat expansion 0.06
Tumor metabolic adaptation induced by L-asparaginase reveals a vulnerability to PARP1/2 inhibitor in B-cell lymphomas 1.00
Rank signaling drives basal cell-lineage infidelity leading to mammary tumorigenesis 0.05
Eukaryote initiation factor 6 modulates small-cell lung carcinoma plasticity via the integrin-FAK signaling axis 0.06
Inhibition of stress resilience and adult hippocampal neurogenesis by platelet-derived LPA16:0 in anxiety 0.05
Succinate receptor 1 restricts hematopoiesis and prevents acute myeloid leukemia progression 0.09
Olutasidenib in recurrent/relapsed locally advanced or metastatic -mutated chondrosarcoma: phase 1b/2 trial 0.27
De novo variants in the splicing factor gene are associated with neurodevelopmental disorders 0.45
EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridge 0.21
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis 0.04
Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial 0.98
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer 0.03
A recurrent pathogenic truncating variant reveals a role for BRCA2-PCAF complex in modulating NF-κB-driven transcription 0.43
Predictive models of melanoma metastasis based on dermatoscopy in an international retrospective human reader study 0.06
INSM1 governs a neuronal progenitor state that drives glioblastoma in a human stem cell model 0.01
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations 0.05
Constitutive activity of an atypical chemokine receptor revealed by inverse agonistic nanobodies 0.13
The AML cellular state space unveils NPM1 immune evasion subtypes with distinct clinical outcomes 0.08
Allosteric regulation of BH3-in-groove interactions by tail anchors of BCL-xL complexes limits BH3 mimetic antagonism 1.00
Cancer cell-derived IL-1β reverses chemo-immunotherapy resistance in non-small cell lung cancer 0.92
Bidirectional communication between nucleotide and substrate binding sites in a type IV multidrug ABC transporter 0.56
Pathogenic variants in cause an X-linked neurodevelopmental disorder modulated by NURF complex composition 0.20
Impact of steroid differentiation on tumor microenvironment revealed by single-nucleus atlas of adrenal tumors 1.00
The Hippo terminal effector YAP boosts enterovirus replication in type 1 diabetes 0.04
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer 0.04
Pathogenic variants reveal candidate genes for prostate cancer germline testing for men of African ancestry 0.02
Hepatitis C virus NS3 helicase contributes to (−) strand RNA synthesis 0.20
ALS/FTD-linked TBK1 deficiency in microglia induces an aged-like microglial signature and drives social recognition deficits in mice 0.86
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial 1.00
The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active 0.80
Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells 0.78
Small round cell sarcoma tumoroid biobank reveals CIC::DUX4 sarcoma vulnerability to MCL-1 inhibition 0.08
Neural function of Netrin-1 in precancerous lesions of the pancreas 0.89
A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas 0.03
Mitochondrial inflexibility ignites tumor immunogenicity in postoperative glioblastoma 0.07
Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study 0.51
The Helicobacter pylori AI-clinician harnesses artificial intelligence to personalise H. pylori treatment recommendations 0.06
JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms 0.90
Different tumour-resident memory T-cell subsets regulate responses to anti-PD-1 and anti-CTLA-4 cancer immunotherapies 1.00
HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity 0.03
HIV status alters immune cell infiltration and activation profile in women with breast cancer 0.06
Alectinib in combination with bevacizumab as first-line treatment in -rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial 0.08
Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS) 0.05
9 2.17
Biallelic variants in the noncoding RNA gene RNU4-2 cause a recessive neurodevelopmental syndrome with distinct white matter changes 0.25
Systematic analysis of snRNA genes reveals frequent variants in dominant and recessive developmental and epileptic encephalopathies 0.70
A repeat expansion in is a major risk factor for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions 0.07
Genomic evolution of pancreatic cancer at single-cell resolution 0.03
De novo and inherited dominant variants in U4 and U6 snRNA genes cause retinitis pigmentosa 0.06
Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations 0.20
Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A 0.02
Dominant variants in major spliceosome U4 and U5 small nuclear RNA genes cause neurodevelopmental disorders through splicing disruption 0.71
Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics 0.12
1 0.04
Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy 0.04
1 0.68
Cell viscosity influences haematogenous dissemination and metastatic extravasation of tumour cells 0.68
22 3.90
Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial 0.64
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial 0.13
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial 0.01
Enhanced dynamic risk stratification of smoldering multiple myeloma 0.01
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial 0.16
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial 0.08
Global and regional cancer burden attributable to modifiable risk factors to inform prevention 0.43
Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trial 0.10
Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial 0.09
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma 0.06
Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma 0.47
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial 0.04
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial 0.12
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial 0.15
Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial 0.89
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial 0.04
Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial 0.08
Pooled analysis of 3,741 stool metagenomes from 18 cohorts for cross-stage and strain-level reproducible microbial biomarkers of colorectal cancer 0.05
Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial 0.03
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase II NeoCOAST-2 trial 0.20
Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial 0.05
Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer 0.09
1 0.17
Heterochromatin boundaries maintain centromere position, size and number 0.17
1 0.25
Clusters of deep intronic RbFox motifs embedded in large assembly of splicing regulators sequences regulate alternative splicing 0.25
1 0.54
Systematic assessment of obesity-related risk factors in renal cancer etiology: A longitudinal risk and mendelian randomization analysis. 0.54
6 1.31
Controlled dynamic remodeling of the spliceosome active site enables the first step of splicing 0.05
Pharmacologic reversion of Merkel cell carcinoma via CBP/p300 inhibition 0.10
A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance 0.04
Intracellular pH regulates ubiquitin-mediated degradation of the MAP kinase ERK3 0.15
PIK3CA gain-of-function mutation in Schwann cells leads to severe neuropathy and aerobic glycolysis through a non-cell autonomous effect 0.92
Mutant IDH1 cooperates with NPM1c or FLT3ITD to drive distinct myeloid diseases and molecular outcomes 0.05
2 2.00
The Safety Standards for Liver Percutaneous Thermal Ablation: A Meta-Analysis of Adverse Events over 15 Years. 1.00
Posttreatment MRI to Predict Pathologic Complete Response of Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy. 1.00
1 0.11
BRAF oncogenic mutants evade autoinhibition through a common mechanism 0.11
10 4.99
Insights into the structure and evolution of the human SAGA complex by affinity-ligand purification 1.00
Single-cell protein activity analysis reveals aberrant myogenesis and IGF2-PI3K pathway dependencies in MYOD1-mutant rhabdomyosarcoma 0.17
Tuning of the RBR1-E2F/DP transcriptional module by the F-box protein FBL17 0.68
A genome-wide genetic screen reveals the P2Y2-integrin axis as a stabilizer of EGFR mutants in non–small cell lung cancer (NSCLC) 0.02
Steroid-dependent metabolic rewiring reveals novel therapeutic and imaging approaches for glioblastoma 0.08
lncRNA LINC-PINT controls lymphatic function and inflammatory profile in lymphedema 1.00
Glial-to-mesenchymal transition of tumor Schwann cells drives the genetic burden in MPNSTs from neurofibromatosis type 1 mouse model 0.92
Reprogramming RIPK3-induced cell death in malignant B cells promotes immune-mediated tumor control 1.00
Structural analysis of HER2-trastuzumab complex reveals receptor conformational adaptation 0.05
TP53 missense–specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer 0.07
3 1.16
Biselective remodeling of the melanoma tumor microenvironment prevents metastasis and enhances immune activation in mouse models 0.06
CAR T cell–mediated bone marrow inflammation causes hematotoxicity and favors clonal hematopoiesis 1.00
Systemic delivery of cadherin 17–specific CAR T cells allows effective and safe targeting of colorectal cancer liver metastases 0.09
3 1.80
Molecular basis for the activation of Aurora A and Plk1 kinases during mitotic entry 0.80
Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells. 0.25
Eliminating separase inhibition reveals absence of robust cohesin protection in oocyte metaphase II 0.75
2 1.50
Ligand’s Role in the Near-Infrared Light-to-Heat Conversion of Au25 Nanoclusters Acting as a Photothermal Agent and Luminescent Lifetime-Based Nanothermometer 1.00
Purinosome Unmasked: Exploring the Molecular-Scale Structure of a Purinosome Complex In Silico 0.50
11 2.68
Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial 0.77
Global variation in patterns of care and time to initial treatment for breast, cervical, and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275 792 women from 103 population-based cancer registries in 39 countries and territories 0.10
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial 0.05
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial 0.04
Adagrasib versus docetaxel in KRAS G12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial 0.15
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial 0.87
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial 0.10
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial 0.10
Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial 0.38
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study 0.05
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial 0.07
1 0.47
Thyroid cancer in adolescents and young adults: a population-based study in 185 countries worldwide 0.47
1 0.17
Breast cancer overall survival, annual risks of death, and survival gap apportionment in sub-Saharan Africa (ABC-DO): 7-year follow-up of a prospective cohort study 0.17
20 4.36
Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration 0.04
Inter-rater reliability of CTCAE assessments with or without EORTC patient-reported outcome data in a mixed cancer population: a multinational, open-label, randomised controlled trial 0.05
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial 0.10
Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial 0.03
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial 0.11
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial 0.10
Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial 0.95
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial 0.06
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial 0.04
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial 1.00
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF V600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study 0.07
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial 0.10
Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial 0.35
TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial 0.16
Health-related quality of life in patients with KRAS G12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial 0.05
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial 0.05
Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial 0.38
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study 0.08
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAF V600E or BRAF V600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study 0.58
Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study 0.08
21 2.17
First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.08
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer 0.11
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer 0.04
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer 0.10
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer 0.05
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer 0.03
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma 0.02
European Study of Prostate Cancer Screening — 23-Year Follow-up 0.09
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer 0.03
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer 0.05
Nivolumab for Resected Stage III or IV Melanoma at 9 Years 0.07
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC 0.05
Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.03
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC 0.04
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer 0.06
Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma 0.96
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer 0.04
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy 0.04
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer 0.08
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer 0.04
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer 0.16
3 1.08
The terminal uridylyltransferase URT1 regulates the transcriptome and primary dormancy of seeds 0.75
The Arabidopsis histone methylation reader MRG2 interacts with eIF4A3 to regulate alternative splicing and circadian rhythms 0.11
Ubiquitin-dependent proteolysis of KNL2 driven by APC/CCDC20 is critical for centromere integrity and mitotic fidelity 0.22
2 2.00
Clustering by patients-related characteristics identifies specific phenotypes with different prognosis after resection of non-small cell lung cancer: a French nationwide study from the Epithor database 1.00
Coexposure to asbestos, mineral wool, crystalline silica and refractory ceramic fibres and risk of lung cancer and mesothelioma 1.00

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.